IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
IGC Pharma, Inc. (NYSE American: IGC) secures a $3 million strategic investment from Bradbury Asset Management, supporting the development of investigational medicines like IGC-AD1. The investment involves issuing 8,823,529 shares of common stock.
The strategic investment of $3 million into IGC Pharma by Bradbury Asset Management is a significant infusion of capital that can have material implications for the company's financial health and operational capabilities. This investment, priced at the closing price of $0.34 per share, indicates a level of confidence in the company's potential, particularly in its investigational medicine IGC-AD1. The issuance of 8,823,529 shares represents a dilution of current shareholders' equity, but it is a common practice for companies seeking to raise funds without incurring debt. Investors should monitor the impact of this dilution on earnings per share and the company's overall market capitalization.
Furthermore, the designation of the funds for general corporate purposes and the advancement of investigational medicines suggests a strategic focus on research and development. The success of IGC-AD1 and other medicines in the pipeline will be important in determining the long-term return on this investment. Short-term, the market may react to the increased liquidity and potential for accelerated company growth. However, the shares being unregistered and not immediately tradable could limit the immediate impact on the stock's liquidity and price volatility.
From a market perspective, strategic investments such as the one made by Bradbury Asset Management in IGC Pharma often signal to the market that institutional investors have vetted and see potential in a company's future. This can be particularly impactful for a company listed on the NYSE American, which is a platform for growth companies. The investment could be interpreted as a positive signal, potentially attracting further attention from other investors and analysts.
It's also important to understand the broader market dynamics. The biopharmaceutical sector is highly competitive and capital-intensive, with investor sentiment often swayed by progress in clinical trials and regulatory approvals. Given that the funds are earmarked for the advancement of IGC-AD1, the market's response may be contingent upon the company's forthcoming announcements regarding the development stages and efficacy of this investigational medicine. The timing of the investment may also be strategic, possibly ahead of significant milestones or data releases that could affect the company's valuation.
The biotech industry is driven by innovation and the potential for breakthrough therapies. IGC Pharma's focus on advancing its investigational medicine IGC-AD1 is indicative of the industry's high-risk, high-reward nature. The $3 million investment from Bradbury Asset Management could be a pivotal moment for the company, providing the necessary resources to reach critical clinical trial milestones or to scale up manufacturing capabilities in anticipation of a successful trial outcome.
Investors should note that the development of investigational medicines is a lengthy and uncertain process, with many potential setbacks. The success of IGC-AD1 is not guaranteed and the investment by Bradbury should be viewed in the context of the inherent risks associated with drug development. However, should IGC-AD1 prove successful, the impact on IGC Pharma's stock could be substantial, with significant implications for patient care in the therapeutic area being targeted by the medicine.
03/26/2024 - 03:00 PM
POTOMAC, Md. --(BUSINESS WIRE)--
IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million Hong Kong ) Limited (“Bradbury”), a leading asset management firm.
On March 22, 2024, the Company entered into a Share Purchase Agreement (the “SPA”) with Bradbury, subject to the terms and subject to the conditions set forth in the SPA. The investment is for approximately $3 million $0.34
The completion of the private placement is subject to customary closing conditions, including approval by the NYSE. Under the terms of the SPA, IGC will issue 8,823,529 shares of common stock. The shares are unregistered and are not immediately tradable.
Please note that this press release does not constitute an offer to sell or a solicitation of an offer to buy these securities. Furthermore, there shall be no sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of the respective state.
About IGC Pharma Inc. (IGC):
IGC Pharma Inc. (“IGC”) is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The Company's mission is to transform the landscape of Alzheimer's treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer's disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently undergoing a Phase 2 clinical trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov , CT05543681). TGR-63 disrupts the progression of Alzheimer's by targeting Aβ plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer's. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer's therapy. In addition to its drug development pipeline, IGC Pharma seeks to leverage Artificial Intelligence (“AI”) for Alzheimer's research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer's.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission ("SEC") filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, and Quarterly Report on Form 10-Q filed with the SEC on February 14, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326654398/en/
Investors
igc@imsinvestorrelations.com
Media
jvasquez@jvprny.com
Source: IGC Pharma Inc.
What is the ticker symbol of IGC Pharma, Inc.?
The ticker symbol of IGC Pharma, Inc. is IGC.
How much was the strategic investment secured by IGC Pharma, Inc.?
IGC Pharma, Inc. secured a $3 million strategic investment.
What is the purpose of the investment from Bradbury Asset Management?
The investment from Bradbury Asset Management will support general corporate purposes and the advancement of investigational medicines like IGC-AD1.
How many shares of common stock will IGC issue under the Share Purchase Agreement?
IGC will issue 8,823,529 shares of common stock under the Share Purchase Agreement.
Are the shares immediately tradable?
The shares issued by IGC are unregistered and not immediately tradable.
